

Supplementary Information

Nanoemulsion-loaded hydrogel coatings for inhibition of bacterial virulence and biofilm formation on solid surfaces

Prateeksha G, Saroj Kanta Barik and Brahma Nand Singh

Herbal Nanobiotechnology Lab, Pharmacology Division, CSIR-National Botanical Research Institute,
Lucknow-226001, India

Supplementary Tables

Table S1. Stability studies of prepared NEs

NE	Stability up to 30 days				Stability up to 60 days				Stability up to 90 days			
	Centrifugation ^a	4 °C	-20 °C	45 °C	Centrifugation ^a	4 °C	-20 °C	45 °C	Centrifugation ^a	4 °C	-20 °C	45 °C
CGF-NE	√	√	√	√	√	√	√	√	√	√	√	√
WGF-NE	√	√	√	√	√	√	√	√	*	*	*	*

√ Neither phase separation nor creaming; * Partial phase separation and creaming

^aCentrifugation for 20 min at 10,000 rpm at 25 °C

Table S2. MIC of CGF-EO, WGF-EO, CGF-NE and WGF-NE

Treatment	^a MIC (%)
CGF-EO	0.5±0.028
WGF-EO	0.3±0.051
CGF-NE	0.1±0.017
WGF-NE	0.025±0.0032

^aMinimum inhibitory concentration (MIC) was calculated using growth curve analysis. MIC is determined as the lowest concentration that exhibited complete inhibition of visible growth of the bacteria. DMSO was used as a solvent control for CGF-EO and WGF-EO, whereas the mixture of DW, surfactant (S; Tween 80) and co-surfactant (CS; propylene glycol) in the ration of 94.7:0.2:0.1 were used as a solvent control for CGF-NE and WGF-NE.

Data represent mean ± SE of six different experiments.

Table S3. MIC and sub-MIC concentrations of eugenol and methyl salicylate^a

Treatment	Concentration (%)
MIC	
Eugenol	0.05±0.002
Methyl salicylate	0.25±0.03
Sub-MIC	
Eugenol	0.005±0.0004
Methyl salicylate	0.025±0.0017

^aMinimum inhibitory concentration (MIC) and sub-MIC was calculated using growth curve analysis. DMSO was used as a solvent control. Data represent mean ± SE of six different experiments.

Table S4. MIC of eugenol-NE and methyl salicylate-NE^a

Treatment	Concentration (%)
MIC	
Eugenol-NE	0.005±0.0007
Methyl salicylate-NE	0.025±0.0043

^aMinimum inhibitory concentration (MIC) was calculated using growth curve analysis. Data represent mean ± SE of six different experiments. The mixture of DW, surfactant (S; Tween 80) and co-surfactant (CS; propylene glycol) in the ration of 94.7:0.2:0.1 were used as a solvent control.

Table S5. Antibiofilm activity of eugenol-NE and methyl salicylate-NE using COMSTAT analysis

Treatment	Volume/Area ($\mu\text{m}^3 \mu\text{m}^{-2}$)	Mean thickness (μm)	Substratum coverage (%)
Control	19.2 \pm 1.83	16.9 \pm 1.44	94 \pm 8.52
Eugenol (0.0005%)	18.9 \pm 1.99	16.6 \pm 1.82	93 \pm 7.74
Eugenol-NE (0.00051%)	2.77 \pm 0.41	2.13 \pm 0.46	9.66 \pm 0.83
Methyl salicylate (0.0025%)	19.1 \pm 1.83	16.9 \pm 1.59	94.4 \pm 9.92
Methyl salicylate -NE (0.0025%)	3.45 \pm 0.41	2.42 \pm 0.22	12 \pm 1.15

The mixture of DW, surfactant (S; Tween 80) and co-surfactant (CS; propylene glycol) in the ration of 94.7:0.2:0.1 were used as a solvent control.

Data represent mean \pm SE of six different experiments.

Table S6. List of primers of *E. coli*

Gene	Forward (5'-3')	Reverse (5'-3')	Product length
<i>escJ</i>	ACGAAAGTCAACCCTCCTCAG	ATCTGAATGACCGATGGTGCT	79
<i>escR</i>	ACCTAGCCAGTTAGTGGCATC	AACCTCTGGCGAGCTGATGA	187
<i>espD</i>	ATTAGTGACGCCCTCTGCTG	ATTTGCTGAGGGTCAACGGT	150
<i>rrsG</i>	ACTGAGACACGGTCCAGACT	TGCGCTTTACGCCCAGTAAT	259
<i>csgF</i>	CTCAGGCCATCCAGTCACAA	AAACCCGAAACCTGGATGGT	178
<i>fimA</i>	CACGACGGTTAATGGTGGGA	GTCCAGGATCTGCACACCAA	310
<i>flhD</i>	ACCTCCGAGTTGCTGAAACA	TGCCAGCTTAACCATTGCG	168
<i>fliA</i>	CGGAAACTGAGGTAGCGGAA	CTCCAGCACTGCACCAATCT	299
<i>qseB</i>	GATTGGCGACGGCATCAAAA	TCAGGATCAGTACCGGCTCA	203
<i>fimC</i>	GGTGGAAAATGCCGATGGTG	AAACTTTCCCGGTCCTGTGG	138
<i>tnaA</i>	TCACCCGCGAAACCTACAAA	AGCCAGTCCAGATTCATGCC	235
<i>bcsA</i>	TTTTCGACTGCGACCACGTA	TAGAACAGCGTGCCTTCGTT	175
<i>csgD</i>	CGCGGCGAATGCTACTTTAC	TCGTTATTAGACGCGCCGAT	149
<i>csgB</i>	AACCTTCTTTGCAGGCGACA	ATGTCGCGGTACGGGTAATC	241
<i>csgG</i>	GCCTGATGTCGGCTATCGAA	TGTCATTCTGCCGTTCTGCT	102
<i>csgA</i>	ATCTGACCCAACGTGGCTTT	CTGAGTTACGTTGACGGTGGA	146
<i>fimD</i>	GGGGAGGCGATGGTAATAGC	AACAAGCACCACCGTATCGT	194
<i>fimH</i>	GCAGTTCTCCTACAGCGGTT	AATGACGACCGAACCAACGA	167
<i>stx1</i>	TTACAGCGTGTTGCAGGGAT	CAGACTGCGTCAGTGAGGTT	112
<i>stx2</i>	GCGACGCCTGATTGTGTAAC	CCCGTAATTTGCGCACTGAG	143
<i>luxS</i>	TTCTTCGTTGCTGTTGATGC	TGGAAGACGTGCTGAAAGTG	152
<i>luxR</i>	CTCGAACGCCTGAACTTTTC	TGGAAGACGTGCTGAAAGTG	231
<i>ecpA</i>	TGCTGACGTAACAGCTCAGG	CCTCGATAGCCACGTCAAAT	164
<i>ecpR</i>	ACATCTGGTCTCCCCATGAC	TACCGCGGATAACCATTCAT	179
<i>tir</i>	CGTCTTCCGTTACGGTACT	ACTTCTGATCCTGGCCACTG	154
Z2200	TTG CGA TAC CAA TGT TGC AT	TGG AAC GGA ATG GTA TTG GT	141
<i>ler</i>	CGA CCA GGT CTG CCC TTC T	GCG CGG AAC TCA TCG AAA	174

Supplementary Figures




Figure S1. Growth kinetics of ECOH in the presence or absence of CGF-EO (a), CGF-NE (b), WGF-EO (c) and WGF-NE (d) with indicated concentrations for the period of 24 h. DMSO was used as a solvent control for CGF-EO and WGF-EO, whereas the mixture of DW, surfactant (S; Tween 80) and co-surfactant (CS; propylene glycol) in the ration of 94.7:0.2:0.1 was used as a solvent control for CGF-NE and WGF-NE.




Figure S2. Cell viability measurement of ECOH. Cells were exposed to mentioned test samples with indicated concentrations for 24 h. Cells were analyzed by fluorescence microscope using bacterial cell viability kit. The mixture of DW, surfactant (S; Tween 80) and co-surfactant (CS; propylene glycol) in the ration of 94.7:0.2:0.1 was used as a solvent control.





Figure S3. GC-MS chromatograms of WGF-EO (a) and CGF-EO (b) .







Figure S4. Impact of eugenol and methyl salicylate on ECOH biofilm formation. (a) The formation of biofilm by ECOH was measured using CV staining assay in the presence of major bioactive compounds after culture for 24 h in 96-well plates. Biofilm formation by ECOH in the presence of essential oils (0.005%) was also confirmed through (a) CV cell staining by phase contrast microscopy and (b) bacterial cell viability kit by fluorescence microscopy. DMSO was used as a solvent control.

Eugenol-NE



Methyl salicylate-NE






Figure S5. Characterization of NEs. DLS particle size distribution of (a) eugenol-NE and (d) methyl salicylate-NE. The insets depict the emulsion of eugenol (1), eugenol-NE (2), emulsion of methyl salicylate (3) and methyl salicylate-NE (4). SEM images of (b) eugenol-NE and (e) methyl salicylate-NE. TEM images of (c) eugenol-NE and (f) methyl salicylate-NE.







Figure S6. Growth kinetics of ECOH in the presence or absence of eugenol (a) eugenol-NE (b), methyl salicylate (c) and methyl salicylate-NE with indicated concentrations for the period of 24 h. DMSO was used as a solvent control for CGF-EO and WGF-EO, whereas the mixture of DW, surfactant (S; Tween 80) and co-surfactant (CS; propylene glycol) in the ratio of 94.7:0.2:0.1 was used as a solvent control for CGF-NE and WGF-NE.

(a)





Figure S7. Anti-biofilm activity of eugenol-NE and methyl salicylate-NE. Inhibition of biofilm in the presence of NEs was measured after treatment of 24 h by ELISA in 96-well plates (a), confocal laser microscopy (b) and CV cell staining (c) techniques. The mixture of DW, surfactant (S; Tween 80) and co-surfactant (CS; propylene glycol) in the ratio of 94.7:0.2:0.1 was used as a solvent control.




Figure S8. Biofilm inhibition of ECOH by eugenol and methyl salicylate, measured by (a) confocal laser microscopy and (b) CV cell staining technique. DMSO was used as a solvent control.






Figure S9. Effect of eugenol-NE and methyl salicylate-NE on the production of virulence factors, namely (a) EPS production, (b) swimming-swarming motilities, and (c) fimbriae production in ECOH cells treated for 24 h. The mixture of DW, surfactant (S; Tween 80) and co-surfactant (CS; propylene glycol) in the ration of 94.7:0.2:0.1 was used as a solvent control.